Additional mining of TCGA genomics data revealed that GATAD2B is also commonly amplified in KRAS mutant cancers in other lineages, including pancreatic ductal adenocarcinoma, where KRAS is mutationally activated in greater than 90% of cases (Fig. 2b)4,9,29,30. This evidence concerns the gene GATAD2B and pancreatic ductal adenocarcinoma.